...
首页> 外文期刊>Pharmacoepidemiology and drug safety >Identification of abacavir hypersensitivity reaction in health care claims data.
【24h】

Identification of abacavir hypersensitivity reaction in health care claims data.

机译:在医疗保健索赔数据中鉴定阿巴卡韦超敏反应。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

PURPOSE: Abacavir is associated with an infrequent but potentially serious hypersensitivity reaction (HSR) that can include a wide range of signs and symptoms. Identification of this reaction through medical insurance claims could provide a simple and efficient means of monitoring the incidence of abacavir hypersensitivity in large populations of patients. METHODS: Using data from a safety study of 948 abacavir users with 22 hypersensitivity events identified from claims and validated through medical record review, we used a recursive partitioning analysis to construct an algorithm to differentiate between patients with and without validated adverse events. Bootstrap resampling techniques provided validation for the analysis. RESULTS: The analysis produced a classification tree with three decision nodes that comprised the best indicators of HSRs. The predictors included any one of several specific symptoms commonly found with this reaction, a claims diagnosis of adverse effect of drug, anaphylactic shock or unspecified allergy, and a discontinuation in abacavir prior to completing a 90-day course of therapy. The algorithm demonstrated 95% sensitivity and 90% specificity when tested using a bootstrap resampling approach with the current data. CONCLUSIONS: A sensitive and specific algorithm for identifying abacavir hypersensitivity from claims was created. This algorithm would permit efficient identification of charts for medical review. Further testing of the algorithm with additional medical claims data for abacavir users will be required to ascertain its validity across databases.
机译:目的:阿巴卡韦与罕见但潜在的严重超敏反应(HSR)相关,该反应可能包括各种各样的体征和症状。通过医疗保险索赔确定这种反应可以提供一种简单有效的方法来监测大批患者中阿巴卡韦超敏反应的发生率。方法:使用对来自948名阿巴卡韦用户的安全性研究的数据,该数据具有从索赔中确定的22种超敏事件,并通过病历审查进行了验证,我们使用了递归分区分析来构建一种算法,以区分有无经过验证的不良事件的患者。引导程序重采样技术为分析提供了验证。结果:分析产生了具有三个决策节点的分类树,该决策树包含了高铁的最佳指标。预测因素包括该反应常见的几种特定症状中的任何一种,声称诊断为药物的不良反应,过敏性休克或未指明的过敏反应,以及在完成90天疗程之前停用abacavir。当使用自举重采样方法对当前数据进行测试时,该算法显示出95%的灵敏度和90%的特异性。结论:创建了一种从索赔中识别阿巴卡韦超敏反应的灵敏且特定的算法。该算法将允许有效标识图表以进行医学检查。将需要针对阿巴卡韦用户对带有附加医疗索赔数据的算法进行进一步测试,以确定其在数据库中的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号